A Tampa health-technology company says it has struck a preliminary deal to bring an AI-powered medication app to tens of thousands of members of a Florida Medicare Advantage-serving HMO, with an initial focus on those who take GLP-1 drugs like Ozempic. DataMEDS AI announced it signed a memorandum of understanding with a Florida-based health maintenance organization that serves Medicare Advantage members to deploy its Health Lives Here app, initially targeting members on GLP-1 receptor agonist medications, with an early focus on those managing obesity and diabetes.
The HMO's name is being withheld at its own request, according to the announcement detailed by valuethemarkets.com. The site reports that the program aims to improve medication adherence along with Healthcare Effectiveness Data and Information Set measures and Centers for Medicare & Medicaid Services star ratings, metrics that directly affect how health plans are evaluated and reimbursed. The same report notes the HMO expects to have between 25,000 and 30,000 members for 2027 once its open enrollment period closes on December 8.
Crucially, the deal is not yet locked in. The companies describe the agreement as a non-binding MOU subject to definitive agreements still to come, according to the report. DataMEDS and the HMO expect to finalize those definitive agreements in the fourth quarter of 2026, with an app rollout to members targeted to begin in the first quarter of 2027 — timelines that remain projections rather than completed steps, per the same account.
Built on an App Launched Just Weeks Ago
Health Lives Here isn't a brand-new product dreamed up for this deal. DataMEDS AI and Tollo Health, LLC announced the app's launch on September 28, with the same initial focus on supporting users of GLP-1 receptor agonist medications, according to a DataMEDS AI announcement. At that time, the Tampa-based company said it intended to broaden the app's target population in the fourth quarter of 2026 to include patients with Long COVID, and later cancer patients.
The app folds in two of DataMEDS' proprietary technologies: its EinsteinRx artificial-intelligence platform and its PharmacyChain blockchain-enabled smart-contract platform, the company said in that same launch release. Those tools are built into Tollo Health's underlying app infrastructure, positioning Health Lives Here as the delivery vehicle for whatever patient populations DataMEDS layers on next.
Part of a Broader GLP-1 Push
The Florida HMO deal lands less than a month after DataMEDS made another move in the same space. On October 14, DataMEDS announced an exclusive U.S. license, revenue-sharing and marketing agreement with REBOOT Health AI covering REBOOT's direct-to-consumer GLP-1 weight-management care platform, according to a report from Nasdaq. The company said it planned to integrate REBOOT's platform into Health Lives Here, with those modules offered to users on a monthly subscription basis.
Taken together, the moves suggest DataMEDS is racing to stake a claim in a fast-growing corner of the drug market. Medicare Part D data compiled by KFF shows two million Part D enrollees took Ozempic alone in 2024, up from fewer than 150,000 in 2019. Gross Part D spending on GLP-1 drugs hit $27.5 billion in 2024, a five-fold jump from five years earlier, while the number of GLP-1 claims climbed from 4.8 million to 21.8 million over that same stretch, per KFF's analysis.
Why Health Plans Are Paying Attention
That surge helps explain why an HMO would entertain a tool meant to track adherence and support members on these medications. The program also aims to improve quality-measure scores that factor into CMS star ratings. KFF's research also notes that CMS's BALANCE payment model is scheduled to begin in 2026 for Medicaid and 2027 for Medicare, a timeline that roughly tracks the rollout window DataMEDS and its Florida partner have set for themselves.
For now, the arrangement remains a statement of intent rather than a signed, binding contract. DataMEDS and the unnamed HMO still have to execute the definitive agreements they're targeting for the fourth quarter of this year before any Florida Medicare Advantage member sees the app on their phone, according to the El Paso Times, which carried the announcement as a press release.
